EPAS1 and obesity disorder: This study intergartes clinical dosing evidence with mechanistic investigation to identify and validate the 3:1 berberine-wogonin ratio as a dual targeting strategy against HIF-1α/HIF-2α pathways, effectively ameliorating obesity-associated insulin resistance.